Recruiting studies: Flt3 Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated
Phase 1 · 23 location(s) · Lomond Therapeutics Holdings, Inc. · NCT06366789 HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Hangzhou Polymed Biopharmaceuticals, Inc. · NCT07137637 A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
Phase 1 · 1 location(s) · Shijiazhuang Yiling Pharmaceutical Co. Ltd · NCT07162116 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patien
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT05886049 Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leuk
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04140487 SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren
Phase 1 · 4 location(s) · Uma Borate · NCT06222580 Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07259707 The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06561880 ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05010122 Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Phase 1 · 13 location(s) · Oryzon Genomics S.A. · NCT05546580 Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Phase 1/Phase 2 · 21 location(s) · Technische Universität Dresden · NCT04385290 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in
Phase 2 · 20 location(s) · French Innovative Leukemia Organisation · NCT06022003 MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07463651 Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05024552 Revumenib in Combination With 7+3 + Midostaurin in AML
Phase 1 · 2 location(s) · Richard Stone, MD · NCT06313437

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.